Related Experiment Video

Updated: Aug 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Recent Progress in Urea-Containing Compounds as Tyrosine Kinase Inhibitors

Farid M Sroor1

  • 1Organometallic and Organometalloid Chemistry Department, National Research Centre, Cairo, 12622, Egypt.

Chemistry & Biodiversity
|August 4, 2026
PubMed

Insights

Urea-based compounds are effective antineoplastic agents targeting tyrosine kinases (TKs). This review details their mechanisms, targets, and the role of computational methods in developing new tyrosine kinase inhibitors (TKIs).

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Pharmacology

Background:

  • Cancer is a leading global cause of death, with dysregulated cellular signaling pathways driving tumorigenesis.
  • Tyrosine kinases (TKs) are crucial enzymes in cell signaling, making them key targets for cancer therapy.
  • Urea motifs, particularly unsymmetrical alkyl- and benzylureas, are vital in drug design for enhancing drug properties.

Purpose of the Study:

  • To review current antineoplastic urea-based tyrosine kinase inhibitors (TKIs).
  • To examine the mechanisms of action and molecular targets of these compounds.
  • To discuss the role of computational technologies and future opportunities in TKI development.

Main Methods:

  • Literature review of contemporary urea-containing compounds targeting TKs.
  • Analysis of mechanisms of action and molecular targets.
  • Exploration of computational approaches in drug discovery for TKIs.

Main Results:

  • Urea-based compounds demonstrate significant potential as TKIs in cancer therapy.
  • Specific urea-containing motifs offer versatile modifications for improved drug properties.
  • Computational technologies accelerate the discovery and repurposing of TKIs.

Conclusions:

  • Urea-based TKIs represent a promising class of antineoplastic agents.
  • Further research and computational strategies are essential for advancing TKI development.
  • Optimizing physicochemical properties through urea modifications enhances therapeutic potential.
Keywords:
FGFRVEGFRanti‐cancerdrug designstructure–activity relationshiptyrosine kinase inhibitorsurea derivatives

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Urea Cycle01:23

Urea Cycle

The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...